BVF as of Dec. 31, 2015
Portfolio Holdings for BVF
BVF holds 30 positions in its portfolio as reported in the December 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 10.2 | $60M | 2.3M | 26.34 | |
| Chemocentryx | 9.2 | $54M | 6.7M | 8.10 | |
| Cti Biopharma | 9.2 | $54M | 44M | 1.23 | |
| Concert Pharmaceuticals I equity | 7.2 | $42M | 2.2M | 18.97 | |
| Oncothyreon | 7.1 | $42M | 19M | 2.22 | |
| Vitae Pharmaceuticals | 6.4 | $37M | 2.1M | 18.10 | |
| Ironwood Pharmaceuticals (IRWD) | 5.8 | $34M | 2.9M | 11.59 | |
| Cytokinetics (CYTK) | 5.2 | $31M | 2.9M | 10.46 | |
| Array BioPharma | 4.8 | $28M | 6.7M | 4.22 | |
| Forward Pharma A/s | 4.7 | $27M | 1.4M | 19.00 | |
| Oncomed Pharmaceuticals | 3.8 | $22M | 991k | 22.54 | |
| Exelixis Inc cnv | 3.8 | $22M | 19M | 1.18 | |
| Loxo Oncology | 3.5 | $20M | 711k | 28.45 | |
| ArQule | 2.5 | $15M | 6.8M | 2.17 | |
| Qlt | 2.4 | $14M | 5.4M | 2.66 | |
| Cytomx Therapeutics (CTMX) | 2.2 | $13M | 609k | 20.87 | |
| Tobira Therapeutics Inc Common Stock Usd 0.0001 | 2.1 | $13M | 1.3M | 10.05 | |
| Five Prime Therapeutics | 2.1 | $13M | 300k | 41.50 | |
| Nivalis Therapeutics | 1.6 | $9.2M | 1.2M | 7.74 | |
| Xenon Pharmaceuticals (XENE) | 1.5 | $9.0M | 1.1M | 8.04 | |
| GTx | 1.3 | $7.8M | 11M | 0.70 | |
| Sunesis Pharmaceuticals | 0.7 | $4.3M | 4.8M | 0.90 | |
| Pain Therapeutics | 0.6 | $3.2M | 1.9M | 1.75 | |
| Catalyst Biosciences | 0.5 | $3.0M | 971k | 3.13 | |
| Globeimmune (GBIM) | 0.4 | $2.5M | 658k | 3.86 | |
| Array Biopharma Inc note 3.000% 6/0 | 0.4 | $2.3M | 2.5M | 0.93 | |
| Mast Therapeutics | 0.3 | $1.6M | 3.7M | 0.42 | |
| Calithera Biosciences | 0.2 | $1.3M | 168k | 7.66 | |
| Biota Pharmaceuticals | 0.1 | $681k | 351k | 1.94 | |
| Nephrogenex | 0.1 | $627k | 392k | 1.60 |
